| Old Articles: <Older 51361-51370 Newer> |
|---|
 |
The Motley Fool
August 24, 2011
Alexander Crawford |
Gold Prices Go Hyperbolic: A Bubble Soon to Burst? Short-sellers think these stocks are set for a pullback, do you agree?   |
The Motley Fool
August 24, 2011
Brian D. Pacampara |
United Therapeutics Shares Got Crushed: What You Need to Know Shares of drugmaker United Therapeutics plunged 17% today after its experimental orally administered lung drug failed in a late-stage clinical trial. |
The Motley Fool
August 24, 2011
Seth Jayson |
Here's Why MeadWestvaco's Earnings Are Worse Than They Look With both 12-month and quarterly CCC running worse than average, MeadWestvaco gets low marks in this cash-conversion checkup. |
The Motley Fool
August 24, 2011
Jim Royal |
Does Flowserve Earn Its Keep? Flowserve showed the kind of steady growth in its returns on invested capital that we like to see until it suffered a sharp decline on its returns in the last four quarters. |
The Motley Fool
August 24, 2011
Seth Jayson |
Here's Why Textron's Latest Report Might Worry You Textron seems to be handling inventory well enough, but the individual segments don't provide a clear signal. |
The Motley Fool
August 24, 2011
Anders Bylund |
This Is a Watershed Moment in OLED History After more than a year of gentle rebuffs, two lovebirds tied a long-term knot. This changes everything. |
The Motley Fool
August 24, 2011
Arundhati Parmar |
Growth Is the Deity Medtronic CEO Omar Ishrak Will Worship CEO Omar Ishrak repeatedly said that a singular focus on growth would be his top priority to transform the company. |
The Motley Fool
August 24, 2011
Morgan Housel |
Bank of America: Tangled in Charlotte's Web The megabank's nightmare. |
The Motley Fool
August 24, 2011
Seth Jayson |
A Hidden Reason Why the Future Looks Bright for Nutraceutical International Nutraceutical International may display positive inventory divergence, suggesting that management sees increased demand on the horizon. |
The Motley Fool
August 24, 2011
Brandon Glenn |
Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge? |
| <Older 51361-51370 Newer> Return to current articles. |
